- A-Z Publications
- Cardiovascular Journal of South Africa
- Previous Issues
- Volume 16, Issue 1, 2005
Cardiovascular Journal of South Africa - Volume 16, Issue 1, 2005
Volume 16, Issue 1, 2005
Author Frans J. MaritzSource: Cardiovascular Journal of South Africa 16, pp 68 –70 (2005)More Less
Extracted from text ... 68 CARDIOVASCULAR JOURNAL OF SOUTH AFRICA Vol 16, No. 1, January/February 2005 Diabetes is already a major health concern in all countries, and type 2 diabetes is undergoing a major escalation, not only in developed 'westernised' countries, but also countries newly exposed to the ravages of a westernised lifestyle, including Sub-Saharan Africa.1 The efficacy of angiotensin converting enzyme inhibitors (ACE inhibitor) in the effective treatment of hypertension and heart failure is backed by a mountain of evidencebased data, and this group of drugs offers the prospect that many of the complications of both type 1 and type 2 diabetes can ..
Source: Cardiovascular Journal of South Africa 16, pp 70 –71 (2005)More Less
Extracted from text ... The PEACE trial, which was designed to assess the value of ACE inhibition therapy in addition to intensive modern therapy in patients with CAD and normal left ventricular function, has not shown additional benefit from ACE inhibition therapy in this low-risk patient group. Trandolapril therapy was, however, associated with effective blood pressure lowering and a reduction in new-onset diabetes. Announcing the results of the PEACE (Prevention of Events with Angiotension Converting Enzyme inhibition) study at the recent American Heart meeting in New Orleans, the co-chairman, Prof M.A. Pfeffer of Harvard Medical School emphasised that while prior studies such as HOPE ..
Source: Cardiovascular Journal of South Africa 16 (2005)More Less
Extracted from text ... 72 CARDIOVASCULAR JOURNAL OF SOUTH AFRICA Vol 16, No. 1, January/February 2005 Cardio News Amlodipine now more affordable Pharma Dynamics is pleased to offer South Africans a cost-effective choice of one of the world's leading cardiovascular medications. The launch of Amloc combines the therapeutic benefit of amlodipine with significant cost savings, to unlock the treatment of hypertension and angina. Amloc is clinically proven to deliver bio-equivalent plasma levels of amlodipine, compared to the originator's product. In addition, Amloc is supported by substantial clinical evidence of its comparable efficacy, safety and tolerability with the originator's amlodipine. This evidence lies at the ..